By combining Nivolumab with CAF-targeting agents, such as TGF-β inhibitors or FAP inhibitors, the therapy can simultaneously reduce the immunosuppressive effects of CAFs and enhance the immune response against tumor cells (114). This evidence concerns the gene FAP and neoplasm.